Full Press Release Details
Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Three-Year Data Highlighting Long-Term Safety and Efficacy of
Embolic Prevention System
to Submit U.S. IDE in Mid-2019
to Host Investor Conference Call at 8:00am ET
Aviv, Israel - November 6, 2018 - InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard
Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today
announced results for the third quarter ending September 30, 2018.
Quarter 2018 highlights:
| Announced preliminary cumulative three-year CGuard Embolic Prevention System (EPS) safety and efficacy data at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 Conference that showed no stroke or stroke-related deaths between 24 and 36 months and the absence of any device related issues in the first 93 patients who had reached the three year follow up in the ongoing PARADIGM-Extend trial | ||
| Received CGuard EPS regulatory approval and initiated commercial launch in Mexico | ||
| Strengthened Intellectual Property portfolio with the issuance of two key United States patents covering the Company's proprietary MicroNet stent jacket and related drug eluting technology across stent-based products | ||
| Announced the opening of the first two Centers of Excellence at the Augusta Hospital Clinic for Vascular Surgery in D sseldorf, Germany, and the Maria Cecilia Hospital in Cotignola, Italy | ||
| Year-to-date CGuard EPS revenue through September 30 was $2.3 million compared to $1.3 million for the comparable period in 2017, an increase of 72% | ||
| Closed an equity financing for gross proceeds of approximately $10 million and completed the recapitalization of the company | ||
| $11.2 million of cash as of September 30, 2018 |
had an eventful and productive third quarter during which we believe we made significant progress in expanding the global commercial
availability of CGuard EPS and bringing it one step closer to becoming the standard of care in stroke prevention following
treatment for carotid artery disease," commented James Barry, PhD, Chief Executive Officer of InspireMD. "The 36-month
data that was presented at the TCT conference adds to the growing and compelling body of clinical evidence that has been compiled
regarding CGuard's long-term sustained benefits to patients relative to conventional carotid stent procedures and, together
with ever increasing Key Opinion Leader support, are driving increased traction across our multi-faceted growth strategy."
addition to continued growth in key existing commercial territories, we remain on-track to file a U.S. IDE expected in mid-2019,
and our new program to educate vascular surgeons about the advantages of CGuard EPS through our Centers of Excellence are having
a positive impact on awareness," Dr. Barry continued. "With our strong balance sheet we believe we have set the stage
for a truly transformational 2019."
for the third quarter ended September 30, 2018 was $769,000 compared to $718,000 during the same period in 2017. The increase
was primarily due to an increase in sales of CGuard EPS as a result of our transition from our prior exclusive distribution
partner for most of Europe to local distributors, and expanding into new geographies such as India, Mexico and Vietnam. The Company's
gross profit for the quarter ended September 30, 2018 was $198,000 compared to $153,000 for the same period in 2017. Gross margin
increased to 25.7% in the three months ended September 30, 2018 from 21.3% in the same period in 2017, driven mainly by a higher
average sales price of MGuard Prime EPS and a reduction in costs of one of the
main components of CGuard EPS. .
operating expenses for the quarter ended September 30, 2018 were $2,177,000, a decrease of 2.7% compared to $2,238,000 for the
same period in 2017. This decrease was primarily due to a decrease in salary expenses, primarily due to a salary related accrual
in 2017 and a decrease in share-based compensation expenses, partially offset by an increase in quality assurance and regulatory
expenses related to annual routine audit activities which included validation reviews required every two years. Financial expenses
for the quarter ended September 30, 2018 were $32,000 compared to $1,000 for the same period in 2017. Net loss for the quarter
ended September 30, 2018 totaled $2,011,000, or $0.05 per basic and diluted share, compared to a net loss of $2,086,000, or $6.56
per basic and diluted share, for the same period in 2017.
for the nine months ended September 30, 2018 was $2,779,000 compared to $1,927,000 for the same period in 2017. The increase was
primarily due to an increase in sales of CGuard EPS as a result of our transition from our prior exclusive distribution
partner for most of Europe to local distributors, and expanding into new geographies such as India and continued focus on expanding
existing markets such as Germany and Italy. The Company's gross profit for the nine months ended September 30, 2018 was $768,000
compared to $374,000 for the same period in 2017. Gross margin increased to 27.6% in the nine months ended September 30, 2018
from 19.4% in the same period in 2017, driven mainly by more efficient utilization of fixed manufacturing resources.
operating expenses for the nine months ended September 30, 2018 were $6,173,000, a decrease of 13.7% compared to $7,157,000 for
the same period in 2017. This decrease was primarily due to a decrease in salary expenses, primarily due to a salary related accrual
in 2017 and a decrease in share-based compensation expenses. These decreases were partially offset by an increase in legal expenses,
as well as costs related to the routine annual audit that we cited earlier. Financial income for the nine months ended September
30, 2018 was $378,000 compared to $155,000 of financial expenses for the same period in 2017, largely due to non-cash income associated
with preferred stock. Net loss for the nine months ended September 30, 2018 totaled $5,027,000, or $0.32 per basic and diluted
share, compared to a net loss of $6,939,000, or $30.42 per basic and diluted share, for the same period in 2017.
of September 30, 2018, cash and cash equivalents were $11,247,000, compared to $3,710,000 as of December 31, 2017.
Call and Webcast Details
conference call will be available via telephone by dialing toll free 877-451-6152 for U.S. callers, or +1 201-389-0879 for international
callers, and referencing conference ID 13683949. To access the webcast, please go to the following link: http://public.viavid.com/index.php?id=131700
webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately
one hour following the call, through November 20, 2018, and can be accessed by dialing 844-512-2921 for U.S. callers or +1 412-317-6671
for international callers and entering conference ID: 13683949.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for Carotid Stenting by providing
outstanding acute results and durable stroke free long-term outcomes.
common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American
under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.
STATEMENTS OF OPERATIONS (1)
dollars in thousands, except per share data)
| Three months ended | Nine months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | |||||||||||||
| Revenues | $ | 769 | $ | 718 | $ | 2,779 | $ | 1,927 | ||||||||
| Cost of revenues | 571 | 565 | 2,011 | 1,553 | ||||||||||||
| Gross Profit | 198 | 153 | 768 | 374 | ||||||||||||
| Operating Expenses: | ||||||||||||||||
| Research and development | 416 | 288 | 898 | 1,041 | ||||||||||||
| Selling and marketing | 605 | 671 | 1,677 | 1,835 | ||||||||||||
| General and administrative | 1,156 | 1,279 | 3,598 | 4,281 | ||||||||||||
| Total operating expenses | 2,177 | 2,238 | 6,173 | 7,157 | ||||||||||||
| Loss from operations | (1,979 | ) | (2,085 | ) | (5,405 | ) | (6,783 | ) | ||||||||
| Financial expenses (income) | 32 | 1 | (378 | ) | 155 | |||||||||||
| Loss before tax expenses | (2,011 | ) | (2,086 | ) | (5,027 | ) | (6,938 | ) | ||||||||
| Tax expenses (Income) | - | - | - | 1 | ||||||||||||
| Net Loss | $ | (2,011 | ) | $ | (2,086 | ) | $ | (5,027 | ) | $ | (6,939 | ) | ||||
| Net loss per share - basic and diluted | $ | (0.05 | ) | $ | (6.56 | ) | $ | (0.32 | ) | $ | (30.42 | ) | ||||
| Weighted average number of shares of common stock used in computing net loss per share - basic and diluted | 40,764,158 | 317,896 | 16,729,052 | 248,907 |
dollars in thousands)
| September 30, | December 31, | |||||||
| 2018 | 2017 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 11,247 | $ | 3,710 | ||||
| Accounts receivable: | ||||||||
| Trade, net | 710 | 643 | ||||||
| Other | 169 | 207 | ||||||
| Prepaid expenses | 145 | 62 | ||||||
| Inventory | 816 | 533 | ||||||
| Total current assets | 13,087 | 5,155 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 400 | 476 | ||||||
| Funds in respect of employee rights upon retirement | 446 | 476 | ||||||
| Total non-current assets | 846 | 952 | ||||||
| Total assets | $ | 13,933 | $ | 6,107 |
| September 30, | December 31, | |||||||
| 2018 | 2017 | |||||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accruals: | ||||||||
| Trade | $ | 456 | $ | 328 | ||||
| Other | 1,891 | 2,134 | ||||||
| Contract liability | 26 | 20 | ||||||
| Total current liabilities | 2,373 | 2,482 | ||||||
| Long-term liabilities: | ||||||||
| Liability for employees rights upon retirement | 608 | 624 | ||||||
| Total long-term liabilities | 608 | 624 | ||||||
| Total liabilities | 2,981 | 3,106 | ||||||
| Redeemable preferred shares | - | 274 | ||||||
| Equity: | ||||||||
| Common stock, par value $0.0001 per share; 150,000,000 shares authorized at September 30, 2018 and December 31, 2017; 36,694,035 and 1,483,556 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 4 | - | ||||||
| Preferred B shares, par value $0.0001 per share; 500,000 shares authorized at September 30, 2018 and December 31, 2017; 17,303 and 27,075 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at September 30, 2018 and December 31, 2017; 61,423 and 741,651 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Preferred D shares, par value $0.0001 per share; 750 shares authorized at September 30, 2018 and December 31, 2017; 0 and 750 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | - | - | ||||||
| Additional paid-in capital | 156,327 | 143,079 | ||||||
| Accumulated deficit | (145,379 | ) | (140,352 | ) | ||||
| Total equity | 10,952 | 2,727 | ||||||
| Total liabilities, redeemable preferred shares and equity | $ | 13,933 | $ | 6,107 |
All 2018 financial information is derived from the Company's 2018 unaudited financial statements, as disclosed in the Company's
Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission; all 2017 financial information is derived from
the Company's 2017 unaudited financial statements, as disclosed in the Company's Quarterly Report on Form 10-Q, filed
with the Securities and Exchange Commission.